Home > Newsletters > FDAnews Drug Daily Bulletin > Appeals Court Upholds Exclusion of Purdue Execs; Rejects ‘Arbitrary’ Penalty Period
FDAnews Drug Daily Bulletin
Aug. 1, 2012 | Vol. 9 No. 150
Appeals Court Upholds Exclusion of Purdue Execs; Rejects ‘Arbitrary’ Penalty Period
A U.S. appeals court has ruled HHS was “unambiguously” justified in excluding three former Purdue Pharma executives from federal healthcare programs after they pleaded guilty to charges the company illegally marketed and promoted its painkiller Oxycontin. Senior Judge Douglas Ginsburg of the U.S. Court of Appeals for the District of Columbia Circuit upheld a lower court’s ruling supporting HHS’ 2008 decision to exclude the execs — CEO Michael Friedman, Chief Medical Officer Paul Goldenheim and General Counsel Howard Udell — from participating in federal healthcare programs.
Drug Industry Daily
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.